

## Aims

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. This is why, nowadays, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the "classic" clinical specialties. Third, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.

With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 12<sup>th</sup> Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 12<sup>th</sup> AIBCC will award the 6th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year.

We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

## Addressed to

Medical oncologists, pathologists, radiologists, radiation oncologists, surgeons, gynaecologists, biologists and nurses.

# **Programme**

## Thursday, September 29th

9.00	Registration				
9.45	Introduction to the Course Pier Franco Conte, Gabriel N. Hortobagyi				
	SESSION I - LIFE BEFORE AND AFTER BREAST CANCER Chairmen: Gabriel N. Hortobagyi, Manuel Zorzi				
10.00	<b>Diet before and after breast cancer</b> Livia S.A. Augustin				
10.30	Fertility after breast cancer diagnosis Fedro Peccatori				
11.00	Breast cancer and sexuality Alessandra Graziottin				
11.30	Coffee break				
	SESSION II - BREAST CANCER IN ITALY Chairmen: Pier Franco Conte, Stefania Gori				
12.00	Breast cancer incidence and mortality over time in Italy Manuel Zorzi				
12.30	The Breast Unit: state of art Claudio Pilerci				
12.50	Indices of appropriateness and efficacy: the Periplo Project Pier Franco Conte				
13.10	Lunch				
	SESSION III - HIGH RISK WOMEN Chairmen: Alberto Amadori, Sibylle Loibl				
14.00	Identification of high risk women: from family history to multigene assays Ettore Capoluongo				
14.30	Risk reduction strategy and management of mutations carriers				

## Multidisciplinary Tumor Board 1 – Management of high risk women Chairmen: Gabriel H. Hortobagyi, Luigi Pescarini

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representative of advocacy group will comment the votes and express their opinions.

Participants: Maia Dzhugashvili, Julia Lynn Fishwick, Valentina Guarneri, Sibylle Loibl, Stefania Migliuolo, Marco Montagna, Monica Morrow, Philip Poortmans, Corrado Tinterri

16.30 Coffee break

#### **SESSION IV - SURGERY**

Chairmen: Fernando Bozza, Pier Franco Conte

17.00 In situ carcinomas: state of art

Monica Morrow

- 17.20 Positive sentinel node: when axillary dissection can be spared Corrado Tinterri
- 17.40 Lipofilling and breast reconstruction: all good or some risks?
  Roberto Gennari
- 18.00 Discussion
- 18.30 Adjourn

## Friday, September 30th

## SESSION V - BREAST CANCER SUBTYPES: ACTIONABLE PROGNOSTIC AND PREDICTIVE PATHWAYS

Chairmen: Pier Franco Conte, Philip Poortmans

- 9.00 **Triple negative breast cancer**Aleix Prat
- 9.30 **HER2+ breast cancers** Sibylle Loibl
- 10.00 **HR+ breast cancers** Stephen Johnston

10.30	Multiple assays to predict risk of early and late recurrence and benefit of treatment in HR+ disease Gabriel N. Hortobagyi				
10.30	Coffee break				
11.30	Multidisciplinary Tumor Board 2 – Biological characterization and adjuvant algorithms Chairmen: Gabriel N. Hortobagyi, Philip Poortmans				
	Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncologists, pathologists, radiation oncologists surgeons and representative of advocacy group will comment the votes and express their opinions.				
	Participants: Pier Franco Conte, Julia Lynn Fishwick, Jassek Jassem Stephen Johnston, Sibylle Loibl, Stefania Migliuolo, Sandra Swain, Enrico Orvieto, Aleix Prat, Corrado Tinterri				
13.00	Lunch				
	SESSION VI - ADJUVANT TREATMENTS OF EARLY BREAST CANCER Chairmen: Sibylle Loibl, Stephen Johnston				
14.00	<b>Triple negative disease</b> Miguel Martin				
14.30	HER2+ disease Valentina Guarneri				
15.00	HR+ disease Jonas Bergh				
15.30	Anti-resorptive agents: role in the adjuvant setting Robert Coleman				
16.00	Radiation therapy: local and systemic efficacy Philip Poortmans				
16.30	Immune checkpoint inhibitors: premises and promises Peter Schmid				

Q&A

Adjourn

17.00

17.15

- 17.45 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2016
- 18.00 Lecture of the Awardee
- 18.30 Cocktail
- 20.00 Adjourn

The Ceremony and the cocktail will take place at MUSME (Museo di Storia della Medicina, Via S. Francesco 94, Padova)

## Saturday, October 1st

## 9.00 Multidisciplinary Tumor Board 3 – Management of advances breast cancer

Chairmen: Pier Franco Conte, Stefano Merigliano

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncologists, pathologists, radiologists, radiation oncologists, surgeons and representative of advocacy group will comment the votes and express their opinions.

Participants: Camillo Aliberti, Jonas Bergh, Julia Lynn Fishwick, Hesham Ahmed Gaballah Elghazaly, Gabriel N. Hortobagyi, Nadia Harbeck, Jassek Jassem, Miguel Martin, Stefania Migliuolo, Donato Nitti, Enrico Orvieto, Philip Poortmans, Aleix Prat, Pietro Ruggieri, Sandra Swain

11.00 Coffee break

## **SESSION VII - NEW DRUGS, NEW HOPES**

Chairman: Jonas Bergh

- 11.30 Targeted agents for HR+ disease
  Nadia Harbeck
- 12.00 New antiHER2 agents
  Sandra Swain
- 12.30 Q&A
- 13.00 Adjourn and final evaluation questionnaire

## **Directors**

#### Pier Franco Conte

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Gabriel N. Hortobagyi

Department of Breast Medical Oncology The University of Texas - MD Anderson Cancer Center Houston (USA)

# Scientific Committee

#### Jonas Bergh

Department of Oncology-Pathology Karolinska Institute and University Hospital Stockholm (SW)

### Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear Medicine University of Ainshams Cairo (EG)

#### Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Jacek Jassem

Department of Oncology and Radiotherapy Medical University of Gdansk (PL)

#### Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

## Sibylle Loibl

German Breast Group Department of Medicine and Research University of Frankfurt (D)

#### Miguel Martin

Medical Oncology Service Hospital Universitario Gregorio Marañon Madrid (S)

#### Donato Nitti

Department of Surgery, Oncology and Gastroenterology University of Padua (I)

## **Philip Poortmans**

President-elect of ESTRO
Department of Radiation Oncology
Radbound University Medical Centre
Nijmegen (NL)

## Speakers & Chairmen

#### Camillo Aliberti

Unit of Oncological Interventional Radiology Istituto Oncologico Veneto Padua (I)

#### Alberto Amadori

Division of Oncological Molecular Diagnostic and Immunology Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

### Livia S.A. Augustin

Department of Nutritional Sciences University of Toronto Toronto

## Jonas Bergh

Department of Oncology-Pathology Karolinska Institute and University Hospital Stockholm (SW)

#### Fernando Bozza

Division of Breast Surgery Istituto Oncologico Veneto IRCCS Padua (I)

#### Ettore Capoluongo

Department of Clinical Molecular Diagnostics University Hospital "Gemelli" Rome (I)

#### Robert E. Coleman

Academic Unit of Clinical Oncology Weston Park Hospital - University of Sheffield Sheffield (UK)

### Pier Franco Conte

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

## Maia Dzhugashvili

Department of Radiation Oncology Instituto Madrileño de Oncología (Grupo IMO) Murcia (E)

## Julia Lynn Fishwick

Salute Donna Milan (I)

## Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and Nuclear Medicine University of Ainshams (E)

#### Roberto Gennari

Department of Surgery AUSL Romagna Ravenna (I)

## Stefania Gori

Division of Medical Oncology Hospital Sacro Cuore Don Calabria Negrar (I)

#### Alessandra Graziottin

Center of Gynaecology and Sessuology Hospital San Raffaele Resnati Milano (I)

#### Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

#### Nadia Harbeck

Department Management, Breast Center and Oncological day clinic Frauenklinik der Universität München (D)

#### Gabriel N.Hortobagyi

Department of Breast Medical Oncology The University of Texas - MD Anderson Cancer Center Houston (USA)

#### Jacek Jassem

Department of Oncology and Radiotherapy Medical University of Gdansk (PL)

#### Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

### Sibylle Loibl

German Breast Group Department of Medicine and Research University of Frankfurt (D)

### Miguel Martin

Medical Oncology Service Hospital Universitario Gregorio Marañon Madrid (S)

## Stefania Migliuolo

Europa Donna Italia Milan (I)

### Stefano Merigliano

Department of Surgery, Oncology and Gastroenterology University of Padua (I)

## Marco Montagna

Hereditary Tumors Group Breast and Ovary Cancer Department of Oncological Molecular Diagnostic and Immunology Istituto Oncologico Veneto University of Padua (I)

#### Monica Morrow

Breast Service, Department of Surgery Memorial Sloan-Kettering Cancer Center New York (USA)

#### Donato Nitti

Department of Surgery, Oncology and Gastroenterology University of Padua (I)

## **Enrico Orvieto**

General Pathology and Cythopatology Unit Department of Medicine-DIMED University of Padua (I)

#### Fedro Alessandro Peccatori

Department of Medical Oncology European Institute of Oncology (IEO) Milan (I)

#### Luigi Pescarini

Department of Radiology Diagnostic Breast Unit Istituto Oncologico Veneto IRCCS University of Padua (I)

#### Claudio Pilerci

Area Social Health Regione Veneto Venezia (I)

### **Philip Poortmans**

President-elect of ESTRO Department of Radiation Oncology Radbound university medical centre Nijmegen (NL)

#### Aleix Prat

Institute of Oncology (VHIO) Vall d'Hebron- Institute of Oncology Barcellona (E)

#### Pietro Ruggieri

Department of Orthopaedics and Orthopaedic Oncology University of Padua (I)

#### Peter Schmid

Centre for Experimental Cancer Medicine Bart Cancer Institute Queen Mary University London (UK)

#### Neda Stjepanovic

High Risk and Cancer Prevention Group Val D'Hebron University Hospital Barcellona (E)

#### Sandra M. Swain

Medical Director Washington Cancer Institute Washington (USA)

#### Corrado Tinterri

Department of Senology Istituto Clinico Humanitas Rozzano (MI)

#### Manuel Zorzi

Veneto Cancer Registry Veneto Region Padua (I)

## Awards & Fellowships

### UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2016

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. Prof. Conte and Prof. Hortobagyi will select the final winner which will be invited to present his/her study during the annual Conference.

## **CASE HISTORIES**

Participants can send one or more case history to the scientific committee. The selected ones will be discussed during one of the three tumor boards (please see the program).

People sending the selected case histories will have to present them and will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement 200,00  $\in$  for Italian participants and  $\in$ 300,00 for European participants).

Case histories should be sent within August 25th.

A confirmation will be sent by email within September 2<sup>nd</sup>.

For further details (such as time limit, number of slides to prepare and so on) please do not hesitate to send an email to manganelli@accmed.org.

## **FELLOWSHIPS**

Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within August  $25^{\text{th}}$ .

The organizing secretariat will confirm the award of the fellowship within September 2<sup>nd</sup> and it will proceed with the organization of logistics.

## **Under 35**

Free admission is available for 3 people "under 35". Registration forms will be accepted on a first-come, first-served basis until spaces will be full. The Organization Secretariat will confirm the registration by email.





Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will request the MCE Accreditation.

The Meeting is addressed to physicians specialized in oncology, radiodiagnostics, radiotherapy, clinical pathology, general surgery, gynaecology and obstetrics. Biologists and nurses. It will not be possible to give credits to physicians specialized in different fields.

The credit certification is subject to:

- attendance at the entire Meeting
- the completion of the Meeting evaluation form
- the completion of the final questionnaire (at least 75% of correct answers).

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2014/2016 can come from a sponsorship.

# Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

## Registration

The registration fee are:

€ 250,00 €150,00 for graduate students € 150,00 for nurses It includes the conference bag, the conference book and all coffee breaks and lunches. It does not include Hotel accommodation, dinners and travel expenses.

Under the article 54 T.U.I.R and within the limits set out therein, the costs of participation in this activity are deductible in determining free-lance income.

To register, please send:

- registration form duly filled out (even when sponsored by a Pharmaceutical Company)
- privacy statement and consent to the use of personal data (as in the back of the form)
- payment

to Accademia Nazionale di Medicina – Palazzina CUP II Piano, Via Massarenti 9, 40138 Bologna (fax 0039 051 6364605 – e.mail: info.bologna@accmed.org, **within September 2**<sup>nd</sup>, **2016.** 

Registration quote can be paid by: non-transferable cheque addressed to Accademia Nazionale di Medicina; bank transfer addressed to: ACCADEMIA NAZIONALE DI MEDICINA, , Banco Popolare - IBAN: IT11M0503401405000000000966 - SWIFT(BIC) CODE: BAPPIT22 (indicate: "Registration of Dr. ... at Course 16\_RE\_2341); Credit Card Details Mastercard. Visa, Eurocard (NO AMEX cards).

Online registration is possible on the website http://meettheprofessor.accmed.org.

By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat. Incomplete registration will NOT be admitted.

The registration will be confirmed by e-mail, please put your e-mail address on the registration form.

## **CANCELLATION**

- if the participants minimum number is not reached, Accademia Nazionale di Medicina will advise by a written communication and proceed with the total refund of the fee.
- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

# Meeting Venue

Centro Congressi Padova A. Luciani Via Forcellini 170/A Padova Tel. +39 049/8033711

## How to reach the meeting venue:

By Car:

The Highway exits are Padova Est, 5 Km from the Meeting Venue Padova Zona Industriale, 6 Km from the Meeting Venue

## By Train:

Padova is in the Center of Veneto, it is easy to reach with the trains Milano-Venezia and Bologna-Venezia. The Meeting Venue is 4 Km from the train station

By Plane

Venezia Airport - Marco-Polo: 43 km (about 40 minutes by car) Treviso Airport - Canova: 63 km (about 50 minutes by car)

# With the patronage of

## **INSTITUTIONS**











## **SCIENTIFIC SOCIETIES**













